Concepedia

Brenda Melendez

BM

Statistics

Publications

11

Citations

809

H-Index

11

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

Houston Methodist

Brenda Melendez is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, immunology, and cancer immunotherapy.

ORCID

Publications per year

2012–2025

11

Publications

11

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Yared Hailemichael, Daniel H. Johnson, Noha Abdel‐Wahab et al. · Cancer Cell · 2022 · 344 citations · Full text

, , +14

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

Sherille D. Bradley, Zeming Chen, Brenda Melendez et al. · Cancer Immunology Research · 2015 · 164 citations · Full text

, , +17

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy

Yasmin A. Lyons, Sunila Pradeep, Sherry Y. Wu et al. · Oncotarget · 2017 · 58 citations · Full text

, , +14

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity

Jungsun Park, Amjad H. Talukder, Seon Ah Lim et al. · Cancer Immunology Research · 2017 · 48 citations · Full text

, , +17

Activation of the Inflammasome and Enhanced Migration of Microparticle-Stimulated Dendritic Cells to the Draining Lymph Node

Ismail M. Meraz, Brenda Melendez, Jianhua Gu et al. · Molecular Pharmaceutics · 2012 · 47 citations

, , +15

1–5 of 11